Hikma launches bupivacaine HCl injection

Bupivacaine HCl injection had a market value of approximately $64 million in the 12 months ending October 2021.
Levy

Hikma is unveiling bupivacaine HCl injection in dosage strengths of 0.25%, 0.5% and 0.75% in 10mL and 30mL.

Bupivacaine HCl injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures and for obstetrical procedures.

[Read more: Hikma intros Kloxxado]

According to IQVIA, bupivacaine HCl injection had a market value of approximately $64 million in the 12 months ending October 2021.

[Read more: Hikma intros micafungin for injection]

X
This ad will auto-close in 10 seconds